Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C)

被引：0

作者：

Schadendorf, Dirk

Flaherty, Keith

Hersey, Peter

Nathan, Paul D.

Garbe, Claus

Milhem, Mohammed M.

Demidov, Lev V.

Hassel, Jessica Cecile

Rutkowski, Piotr

Mohr, Peter

Dummer, Reinhard

Trefzer, Uwe

Larkin, James M. G.

Utikal, Jochen

Casey, Michelle

Santiago-Walker, Ademi

Sherman, Laurie Jill

Martin, Anne-Marie

Wu, Frank S.

Robert, Caroline

机构：

[1] Univ Klinikum Essen, Essen, Germany

[2] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[3] Univ Sydney, Sydney, NSW 2006, Australia

[4] Mt Vernon Canc Ctr, Northwood, Middx, England

[5] Univ Med Ctr, Tubingen, Germany

[6] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA

[7] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[8] Univ Heidelberg Hosp, Hauttumorzentrum, Univ Hautklin, Heidelberg, Germany

[9] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland

[10] Elbeklinikum Buxtehude, Buxtehude, Germany

[11] Univ Zurich Hosp, CH-8091 Zurich, Switzerland

[12] Charite, Melanoma Ctr, D-13353 Berlin, Germany

[13] Royal Marsden Hosp NHS Fdn Trust, London, England

[14] Heidelberg Univ, German Canc Res Ctr DKFZ, Heidelberg, Germany

[15] Heidelberg Univ, Univ Med Ctr Mannheim, Heidelberg, Germany

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Inst Gustave Roussy, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9020

引用

页数：1